UC DAVIS Researchers hone in on Angelman Syndrome Treatment
FAST (Foundation for Angelman Syndrome Therapeutics) has funded two research labs at the University of California, Davis (UC Davis) to further investigation
FAST (Foundation for Angelman Syndrome Therapeutics) has funded two research labs at the University of California, Davis (UC Davis) to further investigation
How FAST Is Changing The Landscape Of Angelman Research When you set out to cure an ‘incurable’ genetic disorder, you need three things: a comprehensive,
Ketone ester supplementation attenuates seizure activity, and improves behavior and hippocampal synaptic plasticity in an Angelman syndrome mouse model
Read more about the exciting work that has earned the Segal Lab $1.1 Million for research.
Additional Gene Therapy Approach For Angelman Syndrome Explored By Paula Evans The Foundation for Angelman Syndrome Therapeutics (FAST) is delighted to annou
RDr. Dindot’s 3 goals, which have been the focus of his AS research through the FIRE initiative, are;
Mechanisms regulating imprinting of UBE3A in ne
Dr Anne Anderson of the FAST FIRE team works on evaluating seizure and behavioral phenotypes (characteristics) in AS mice and how this information can be use
Help Ovid Therapeutics Color Our World Beautiful! An Announcement from Ovid Therapeutics Ovid Therapeutics is working towards initiating its phase II study o
Edwin Weeber, Ph.D. is a Professor in the Department of Molecular Pharmacology and Physiology and the Chief Scientific Officer at the University of South Flo
Stakeholders meet to develop Biomarkers and Outcome Measures for clinical trials in Angelman Syndrome We are thrilled to announce that the Angelman Syndrome